The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales

The epidemiology of herpes zoster and post-herpetic neuralgia (PHN) was quantified from a variety of data sources and the potential cost-effectiveness of vaccination assessed. The annual incidence and severity of zoster increases sharply with age, as measured by physician consultation and hospitalis...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2001-04, Vol.19 (23-24), p.3076-3090
Main Authors: Edmunds, W.J, Brisson, M, Rose, J.D
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Biological and medical sciences
British Isles
British Isles, England
British Isles, Wales
Child
Child, Preschool
Cost-Benefit Analysis
Cost-effectiveness analysis
England - epidemiology
Epidemiology. Vaccinations
General aspects
Herpes zoster
Herpes Zoster - economics
Herpes Zoster - epidemiology
Herpes Zoster - immunology
Herpes Zoster - prevention & control
Herpesvirus Vaccines - economics
Herpesvirus Vaccines - pharmacology
Humans
Infant
Infant, Newborn
Infectious diseases
Medical sciences
Middle Aged
Models, Economic
post-herpetic neuralgia
Sensitivity and Specificity
Vaccination
Wales - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The epidemiology of herpes zoster and post-herpetic neuralgia (PHN) was quantified from a variety of data sources and the potential cost-effectiveness of vaccination assessed. The annual incidence and severity of zoster increases sharply with age, as measured by physician consultation and hospitalisation rates, average length of stay, average proportion of cases developing PHN and the age-specific case-fatality ratio. Combining these data with information on health related quality of life results in an estimated loss of 20 000 quality adjusted life years (QALYs) annually in England and Wales from herpes zoster (17 400 due to PHN). The current cost of treating herpes zoster associated disease is estimated to be £47.6m annually. Since both the health and economic burden are high, vaccination of the elderly is expected to be cost-effective under most scenarios, the attractiveness of immunisation increasing with age due to the increased burden of disease in the very elderly.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(01)00044-5